Haemophilia trials in China

In China 30 Also abroad 128

30 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in China
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, PK/PD Characteristics, and Efficacy of SCTB10
Where
Tianjin
Age
18 years to 50 years
People
12
Run by
Sinocelltech Ltd.
See details and how to joinNCT07847697
Phase 3Taking people
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Where
Beijing, Chengdu, Fuzhou, Guangzhou, Tianjin
Age
12 years and over
People
360 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07416604 · EU 2025-522435-33-00
Phase 1Not yet taking people in China
Lentiviral FIX Gene Therapy
Where
Shenzhen
Age
2 years to 65 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03961243
Phase 1Not yet taking people in China
Lentiviral FVIII Gene Therapy
Where
Shenzhen
Age
2 years to 65 years
People
10
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03217032
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
Where
Beijing, Wuhan
Age
1 year to 11 years
People
85 worldwide
Run by
Sanofi
See details and how to joinNCT07285460 · EU 2025-521858-42-00
Phase 3Taking people
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Where
Beijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan
Age
1 year to 74 years
People
245 worldwide
Run by
Pfizer
See details and how to joinNCT05145127 · EU 2022-500470-33-00
Phase 3Taking people
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
Where
Beijing
Age
12 years and over
People
138 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07416526 · EU 2025-522434-32-00
Phase 3Taking people
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
Where
Beijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05611801 · EU 2022-500495-65-00
No phaseNot yet taking people in China
A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07789587
No phaseNot yet taking people in China
A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A
Where
Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07788469
Phase 1/2Taking people
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
Where
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an, Zhengzhou
Age
18 years to 65 years
People
76
Run by
Shanghai RAAS Blood Products Co., Ltd.
See details and how to joinNCT07644832
No phaseTaking people
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry
Where
Tianjin, Xiamen
Age
12 years and over
People
100
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06992076
Phase 3Taking people
Safety of KN057 Prophylaxis in Patients With Haemophilia A or B
Where
Tianjin
Age
12 years to 65 years
People
70
Run by
Suzhou Alphamab Co., Ltd.
See details and how to joinNCT07545395
Phase 2/3Taking people
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
Where
Beijing, Changsha, Chengde, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an
Age
18 years and over
People
55
Run by
Shanghai Xinzhi BioMed Co., Ltd.
See details and how to joinNCT06111638
Phase 3Taking people
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
Where
Beijing
Age
Up to 6 years
People
36
Run by
Sinocelltech Ltd.
See details and how to joinNCT07437404
No phaseTaking people
National Longitudinal Cohort of Hematological Diseases
Where
Tianjin
People
2,300
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04645199
Phase 4Taking people
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
Where
Tianjin
Age
12 years to 65 years
People
30
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07406139
Phase 3Taking people
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
Where
Beijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou
Age
18 years to 65 years
People
50
Run by
Gritgen Therapeutics Co., Ltd.
See details and how to joinNCT06833983
No phaseTaking people
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Where
Xining
People
1,000
Run by
Yigeng Cao,MD,PhD
See details and how to joinNCT07205523
Phase 4Taking people
An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
Where
Tianjin
Age
18 years and over
People
25
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05849740
No phaseTaking people
Gene Therapy for Chinese Hemophilia A
Where
Tianjin
Age
18 years and over
People
12
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT04728841
Phase 4Taking people
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
Where
Beijing
Age
0 years to 18 years
People
110
Run by
Runhui WU
See details and how to joinNCT06864975
No phaseTaking people
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
Where
Tianjin
Age
18 years to 65 years
People
6
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05630651
Phase 1/2Taking people
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
Where
Tianjin
Age
18 years and over
People
21
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05641610
Phase 4Taking people
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
Where
Tianjin
Age
14 years to 65 years
People
50
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05888870